Tag: development

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the...

ISTANBUL, June 10, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") attracted widespread attention at KOMATEK 2026 in Istanbul with...

TAIPEI, June 10, 2026 /PRNewswire/ -- HKC, ANTGAMER, and KOORUI have successfully concluded their presence at COMPUTEX 2026. Under the theme "Win Beyond the...

Dual initiatives advance Group strategy by tripling parcel processing capacity to lower cost-to-serve and enhancing public convenienceSINGAPORE, June 10, 2026 /PRNewswire/ -- Singapore Post...

Minami Maeda appointed as CEO to drive faster, more focused execution toward U.S. commercial launchMickey Mikitani will continue to provide strategic direction and remains...

Peer-nominated award honors leaders who exemplify community impact and a commitment to changing the odds for kids across California.SANTA ANA, Calif., June 9, 2026...

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

One of Singapore's first dedicated commercial-scale LED Chip-on-Board (CoB) packaging facilities — anchoring a vertically integrated global semiconductor and advanced electronics supply chain spanning...

Enhancing ASIC Design Services Layout, Expanding Global Footprint and Growth PerformanceTAIPEI, June 10, 2026 /PRNewswire/ -- QBit Semiconductor (TWSE: 7913; hereinafter referred to as...

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...